GlassScriptPhysician profile
Javier Flores
NPI 1700839057
$67,410.81
in general payments reported to CMS, 2019-2025
43 companies · $2,644 in 2025
The $2,644 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $15K · 2021: $9,476 · 2022: $1,808 · 2023: $5,194 · 2024: $3,258 · 2025: $2,644.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,984 · Consulting Fee: $2,000 · Education: $98.27 · Travel and Lodging: $12.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,984.42 |
| Consulting Fee | $2,000.00 |
| Education | $98.27 |
| Travel and Lodging | $12.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51,412.11 | 2019-2025 | |
| Janssen Biotech, INC. | $3,596.14 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $2,627.84 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,195.56 | 2019-2025 | Jublia, Arazlo, Siliq |
| Leo Pharma INC. | $1,327.06 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $1,020.18 | 2019-2025 | |
| Lilly USA, LLC | $954.82 | 2019-2025 | Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $575.67 | 2019-2025 | |
| Incyte Corporation | $505.34 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $323.83 | 2019-2025 | Dupixent, Libtayo |
| Amgen INC. | $304.53 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $295.32 | 2019-2024 | Winlevi, Absorica Ld, Odomzo |
| Arcutis Biotherapeutics, INC. | $295.24 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $242.88 | 2020-2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $218.04 | 2022-2024 | Tremfya |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $208.73 | 2019-2021 | |
| Ucb, INC. | $158.66 | 2019-2024 | Bimzelx |
| Almirall LLC | $156.67 | 2019-2025 | Klisyri |
| Biofrontera INC. | $143.32 | 2019-2020 | |
| Genzyme Corporation | $133.70 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.47 | 2024-2025 | Spevigo |
| Epi Health, LLC | $57.61 | 2019 | |
| Organogenesis INC. | $52.60 | 2021 | |
| Mayne Pharma Commercial LLC | $50.31 | 2023 | |
| Journey Medical Corporation | $41.72 | 2022-2025 | |
| Aclaris Therapeutics, INC. | $40.62 | 2019 | |
| Medtronic, INC. | $39.43 | 2021 | |
| Celgene Corporation | $38.11 | 2019 | |
| Dermira, INC. | $35.89 | 2019-2020 | |
| Organon LLC | $31.32 | 2025 | Vtama |
| Kerecis Limited | $24.51 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Ani Pharmaceuticals, INC. | $23.43 | 2025 | Oxistat |
| Paratek Pharmaceuticals, INC. | $22.73 | 2024 | Nuzyra |
| Nabriva Therapeutics, Plc | $22.64 | 2022 | |
| Verrica Pharmaceuticals INC. | $22.25 | 2023 | Ycanth |
| Merz North America, INC. | $20.59 | 2019 | |
| Vyne Pharmaceuticals INC. | $18.97 | 2020 | |
| Bioventus LLC | $16.53 | 2022 | |
| Merck Sharp & Dohme LLC | $16.50 | 2019 | |
| Icad, INC | $16.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.83 | 2023 | Sotyktu |
| Hill Dermaceuticals, INC. | $13.99 | 2020 | |
| Allergan, INC. | $13.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.